Wednesday, April 17, 2019 12:29:11 PM
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 11, 2019:
i. Dr. Carlos Rizo was appointed as a director by the Company’s sole director, Daniel Tsai.
ii. Upon the election of Dr. Rizo, Daniel Tsai, the Company’s sole director and officer, resigned as director and officer.
iii. Dr. Carlos Rizo was appointed as chief executive officer, chief financial officer, president and secretary.
Dr. Rizo, age 48, has been the chief executive officer of Bwellmed International Holdings, Ltd., a Canadian agri-pharma company with a wholly-owned subsidiary in Colombia which is licensed to product pharmaceutical grade, non-psychoactive cannabis products for medicinal, industrial and scientific purposes in Colombia which Dr. Rizo founded in 2016. Through eHealth in Motion, Ltd., a company wholly owned by Dr. Rizo, Dr. Rizo has provided consulting services relating to customized web tools for patients, health professionals and non-profit organizations. Dr. Rizo received his medical degree from Universidad del Roasario in Colombia and holds fellowships in Consumer Health Informatics and eHealth Innovation from the University Health Network in Toronto, Canada.
Mr. Tsai did not resign because of a disagreement on any matter relating to the Company’s operations, policies or practices.
Item 8.01 Other Events .
During 2018, we were engaged in the development of the business of selling computer equipment which can be used for the mining of cryptocurrency. As a result of the decline in the price of cryptocurrency, which made the purchase of our equipment uneconomical, we have discontinued that business, which will be reflected as a discontinued operation. We are in the process of evaluating potential business opportunities, although we cannot assure you that we will be able to acquire or commence profitable operations.
Recent MYCB News
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/21/2024 07:20:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 08:41:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 06:58:51 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM